Scientists hunt for clues to predict CAR-T success in hard-to-treat lymphoma
NCT ID NCT07236203
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study aims to find out which factors help predict whether CAR-T therapy will work in people with relapsed or refractory large B-cell lymphoma. Researchers will look at patient health records, tumor features, and immune system changes in 80 participants. The goal is to better understand who benefits most from this treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LARGE B-CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan University Shanghai Cancer Center
RECRUITINGShanghai, Shanghai Municipality, 200231, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- New combo therapy aims to boost remission in Hard-to-Treat lymphoma
- Engineered immune cells get a boost: new combo therapy targets Hard-to-Treat blood cancers
- New combo aims to boost lymphoma control in older patients
- New hope for lymphoma patients when CAR-T fails
- New cocktail aims to tackle tough lymphoma
- Could licorice root make CAR-T cancer therapy safer and stronger?